Bioanalysis of Biotherapeutics

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of analytical and bioanalytical techniques

• Publication date

  2013-05-10

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.4172/2155-9872.1000E116
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery fit-for-purpose ligand-binding PK assays: what's really important?

  2013cited by this paper
• Bioanalytical challenges in the development of biosimilars

  2013cited by this paper
• Capillary microsampling and analysis of 4-µl blood, plasma and serum samples to determine human α-synuclein elimination rate in mice.

  2013cited by this paper
• An extended range generic immunoassay for total human therapeutic antibodies in preclinical pharmacokinetic studies.

  2013cited by this paper
• Sequential protein and peptide immunoaffinity capture for mass spectrometry-based quantification of total human β-nerve growth factor.

  2013cited by this paper
• Simultaneous Analysis of Multiple Monoclonal Antibody Biotherapeutics by LC-MS/MS Method in Rat Plasma Following Cassette-Dosing

  2013cited by this paper
• Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.

  2013cited by this paper
• Ligand Binding Assays in the 21st Century Laboratory: Recommendations for Characterization and Supply of Critical Reagents

  2012cited by this paper
• In vitro and in vivo stability and pharmacokinetic profile of unacylated ghrelin (UAG) analogues.

  2012cited by this paper
• Analytical measurement of PEGylated molecules.

  2012cited by this paper
• Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry.

  2012cited by this paper
• Comparison of triple quadrupole and high-resolution TOF-MS for quantification of peptides.

  2012cited by this paper
• Large molecule bioanalysis using Q-TOF without predigestion and its data processing challenges.

  2012cited by this paper
• Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry.

  2012cited by this paper
• Pharmacokinetic Considerations for Antibody Drug Conjugates

  2012cited by this paper
• A universal surrogate peptide to enable LC-MS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein drug candidates in pre-clinical animal studies.

  2012cited by this paper
• Practical quantitative and kinetic applications of bio-layer interferometry for toxicokinetic analysis of a monoclonal antibody therapeutic.

  2012cited by this paper
• Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

  2012cited by this paper
• Bioanalysis of Oligonucleotide Therapeutics

  2011cited by this paper
• Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis.

  2011cited by this paper
• Bioanalytical approaches to analyzing peptides and proteins by LC--MS/MS.

  2011cited by this paper
• Antibody Conjugate Therapeutics: Challenges and Potential

  2011cited by this paper
• Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development

  2011cited by this paper
• Direct Quantitative Analysis of a 20 kDa PEGylated Human Calcitonin Gene Peptide Antagonist in Cynomolgus Monkey Serum Using In-Source CID and UPLC-MS/MS

  2011cited by this paper
• Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.

  2011cited by this paper
• Validation of a bioanalytical method for the quantification of a therapeutic peptide, ramoplanin, in human dried blood spots using LC-MS/MS.

  2011cited by this paper
• Dual ligation hybridization assay for the specific determination of oligonucleotide therapeutics.

  2011cited by this paper
• Tunable degradation of maleimide-thiol adducts in reducing environments.

  2011cited by this paper
• Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry.

  2011cited by this paper
• Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals.

  2010cited by this paper
• Immunoaffinity purification using anti-PEG antibody followed by two-dimensional liquid chromatography/tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma.

  2010cited by this paper
• Relative Potency Estimation in Parallel-Line Assays – Method Comparison and Some Extensions

  2010cited by this paper
• Strategies to minimize variability and bias associated with manual pipetting in ligand binding assays to assure data quality of protein therapeutic quantification.

  2010cited by this paper
• Application of multi-factorial design of experiments to successfully optimize immunoassays for robust measurements of therapeutic proteins.

  2009cited by this paper
• The promises and pitfalls of RNA-interference-based therapeutics

  2009cited by this paper
• Workshop Report and Follow-Up—AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples—Implications of Crystal City Recommendations

  2009cited by this paper
• A new approach for pharmacokinetics of single-dose cetuximab in rhesus monkeys by surface plasmon resonance biosensor.

  2009cited by this paper
• A global benchmark study using affinity-based biosensors.

  2009cited by this paper
• Single domain antibodies: promising experimental and therapeutic tools in infection and immunity

  2009cited by this paper
• Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.

  2008cited by this paper
• Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.

  2008cited by this paper
• Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators.

  2008cited by this paper
• Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.

  2008cited by this paper
• Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

  2008cited by this paper
• Contribution of linker stability to the activities of anticancer immunoconjugates.

  2008cited by this paper
• Therapeutic applications of aptamers

  2008cited by this paper
• Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry.

  2008cited by this paper
• Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays

  2007cited by this paper
• Risk management for analytical methods based on the total error concept: Conciliating the objectives of the pre-study and in-study validation phases

  2007cited by this paper
• A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs

  2007cited by this paper
• Antisense technology: a selective tool for gene expression regulation and gene targeting.

  2007cited by this paper
• Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays

  2007cited by this paper
• Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab

  2007cited by this paper
• Scientific and regulatory considerations on the immunogenicity of biologics.

  2006cited by this paper
• Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.

  2006cited by this paper
• Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins*

  2006cited by this paper
• Therapeutic potential of Toll-like receptor 9 activation

  2006cited by this paper
• Discovery and development of anticancer aptamers

  2006cited by this paper
• Analysis of nucleic acid constituents by on‐line capillary electrophoresis‐mass spectrometry

  2005cited by this paper
• Arming antibodies: prospects and challenges for immunoconjugates

  2005cited by this paper
• In vivo deamidation characterization of monoclonal antibody by LC/MS/MS.

  2005cited by this paper
• An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen.

  2005cited by this paper
• Development of an Ion-Pair Reverse-Phase Liquid Chromatographic/Tandem Mass Spectrometry Method for the Determination of an 18-Mer Phosphorothioate Oligonucleotide in Mouse Liver Tissue

  2005cited by this paper
• Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry.

  2005cited by this paper
• Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry

  2005cited by this paper
• In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.

  2005cited by this paper
• Interferences in immunoassay.

  2004cited by this paper
• Pharmacokinetics of Gemtuzumab Ozogamicin as a Single‐Agent Treatment of Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

  2004cited by this paper
• Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice

  2004cited by this paper
• Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

  2004cited by this paper
• Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

  2004cited by this paper
• Bioanalytical Method Validation

  2004cited by this paper
• Mismatch cleavage by single-strand specific nucleases.

  2004cited by this paper
• Immunogenicity of therapeutic proteins.

  2003cited by this paper
• Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules

  2003cited by this paper
• Drug metabolites in safety testing.

  2002cited by this paper
• Interferences in immunoassay--still a threat.

  2000cited by this paper
• Assay of Plasma Insulin in Human Subjects by Immunological Methods

  1959cited by this paper

• No citing papers are available for this paper.